

Pablo Barreiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4224645/publications.pdf>

Version: 2024-02-01

240
papers

7,995
citations

44066

48
h-index

74160

75
g-index

251
all docs

251
docs citations

251
times ranked

6727
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009, 23, 689-696.	2.2	250
2	Pegylated IFN- α 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028.	2.2	183
3	Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982.	1.1	183
4	Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315.	4.1	177
5	Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2005, 40, 1358-1361.	5.8	176
6	Antiretroviral drugs and liver injury. <i>Aids</i> , 2008, 22, 1-13.	2.2	163
7	Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676.	4.0	157
8	Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 177-182.	2.1	148
9	Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. <i>Aids</i> , 2000, 14, 807-812.	2.2	143
10	Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. <i>Clinical Infectious Diseases</i> , 2004, 38, 430-432.	5.8	128
11	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46.	2.2	127
12	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.	2.2	120
13	Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C>T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295.	5.8	116
14	Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 383-386.	2.2	109
15	Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.	5.8	96
16	Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 324-326.	2.1	94
17	Liver cirrhosis in HIV-Infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008, 15, 165-172.	2.0	94
18	Main differences between the first and second waves of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 105, 374-376.	3.3	92

#	ARTICLE	IF	CITATIONS
19	Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2008, 15, 427-433.	2.0	87
20	Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 699-704.	3.0	87
21	Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1549-1553.	5.8	85
22	Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , 2010, 24, 1171-1176.	2.2	84
23	Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.	3.0	81
24	Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. <i>Antiviral Therapy</i> , 2008, 13, 103-108.	1.0	80
25	Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 401-405.	2.1	79
26	Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV-Infected Patients with Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2007, 195, 973-979.	4.0	79
27	Management of chronic hepatitis B and C in HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 815-818.	3.0	78
28	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	2.2	75
29	Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. <i>Aids</i> , 2000, 14, 2153-2157.	2.2	74
30	Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir. <i>Antiviral Therapy</i> , 2008, 13, 429-438.	1.0	74
31	Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007, 22, 2353-2358.	0.9	72
32	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205.	3.0	70
33	Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, 11-16.	2.0	67
34	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17.	2.0	65
35	Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1365-1373.	3.0	64
36	Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies. <i>Antiviral Therapy</i> , 2004, 9, 987-992.	1.0	63

#	ARTICLE	IF	CITATIONS
37	SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. <i>HIV Clinical Trials</i> , 2002, 3, 186-194.	2.0	58
38	Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. <i>Aids</i> , 2002, 16, 245-249.	2.2	57
39	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170.	1.8	57
40	Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 47-52.	2.0	57
41	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	5.8	56
42	Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. <i>Aids</i> , 2014, 28, 2389-2394.	2.2	56
43	Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006, 6, 234-245.	2.0	55
44	Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving Anti-HBV Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 842-848.	1.1	55
45	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	4.0	55
46	Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 557-561.	2.1	53
47	Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1215-1223.	1.8	53
48	Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 466-484.	1.3	52
49	Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039.	5.8	51
50	Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.	3.1	48
51	Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 923-932.	2.4	47
52	Drug interactions with new hepatitis C oral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 333-341.	3.3	46
53	Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. <i>Antiviral Therapy</i> , 2009, 14, 187-193.	1.0	46
54	Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. <i>Liver International</i> , 2013, 33, 1357-1362.	3.9	45

#	ARTICLE	IF	CITATIONS
55	Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. <i>Antiviral Therapy</i> , 2012, 17, 921-926.	1.0	44
56	Baseline Serum Hepatitis C Virus (HCV) RNA Level and Response at Week 4 Are the Best Predictors of Relapse After Treatment With Pegylated Interferon Plus Ribavirin in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 439-444.	2.1	43
57	New antivirals for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 843-851.	4.1	43
58	Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2007, 195, 1181-1183.	4.0	42
59	Sustained Virological Response following HCV Therapy is Associated with Non-Progression of Liver Fibrosis in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2006, 11, 869-878.	1.0	42
60	Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 1-19.	2.4	41
61	Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227.	1.1	41
62	Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2008, 49, 916-922.	3.7	40
63	Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825.	1.1	39
64	Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822.	3.0	39
65	Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses. <i>Journal of Infectious Diseases</i> , 2013, 207, 1379-1388.	4.0	39
66	HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629.	1.8	38
67	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	3.1	38
68	Third wave of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 107, 212-214.	3.3	38
69	The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013, 15, 25-31.	1.0	38
70	Hepatitis C cure with antiviral therapy “ benefits beyond the liver. <i>Antiviral Therapy</i> , 2015, 21, 1-8.	1.0	37
71	Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008, 22, 2535-2537.	2.2	36
72	Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 387-391.	2.0	35

#	ARTICLE	IF	CITATIONS
73	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.	5.8	35
74	Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 790-795.	2.0	35
75	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 881-886.	1.0	35
76	Hepatitis delta and HIV infection. <i>Aids</i> , 2017, 31, 875-884.	2.2	35
77	Enfuvirtide Is Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 583-585.	1.1	34
78	Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 806-809.	3.0	33
79	Influence of a Single Nucleotide Polymorphism at the Main Ribavirin Transporter Gene on the Rapid Virological Response to Pegylated Interferon-Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 1185-1191.	4.0	33
80	Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2004, 9, 505-509.	1.0	33
81	Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753.	2.2	32
82	Temporary hospitals in times of the COVID pandemic. An example and a practical view. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 280-288.	1.3	32
83	Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 325-330.	2.0	31
84	Pharmacogenetics of hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 523-529.	3.0	30
85	Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323.	1.8	30
86	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017, 31, 1653-1663.	2.2	30
87	Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 657-662.	1.0	30
88	Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 825-829.	1.1	29
89	The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study. <i>Age and Ageing</i> , 2021, 50, 1038-1047.	1.6	29
90	Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59.	2.2	28

#	ARTICLE	IF	CITATIONS
91	A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0219921.	3.9	28
92	Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. <i>Antiviral Therapy</i> , 2008, 13, 429-37.	1.0	28
93	Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 364-368.	2.1	27
94	Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1117-1122.	5.8	27
95	Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. <i>HIV Clinical Trials</i> , 2006, 7, 246-250.	2.0	26
96	Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096502.	1.8	26
97	Management and Treatment of Chronic Hepatitis C in HIV Patients. <i>Seminars in Liver Disease</i> , 2012, 32, 138-146.	3.6	25
98	Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000, 14, 1672-1673.	2.2	25
99	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.	2.2	24
100	Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008, 15, 363-369.	2.0	24
101	Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.	2.1	24
102	The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.	4.1	24
103	Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134.	2.2	24
104	Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014, 28, 1473-1478.	2.2	24
105	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7.	4.1	24
106	Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. <i>Antiviral Therapy</i> , 2008, 13, 103-7.	1.0	24
107	Higher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 333-337.	1.1	23
108	Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649.	3.2	23

#	ARTICLE	IF	CITATIONS
109	Antiretroviral drug-related toxicities â€“ clinical spectrum, prevention, and management. Expert Opinion on Drug Safety, 2013, 12, 697-707.	2.4	23
110	Emerging Challenges in Managing Hepatitis B in HIV Patients. Current HIV/AIDS Reports, 2015, 12, 344-352.	3.1	23
111	Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy, 2017, 18, 1235-1242.	1.8	23
112	Simplification of antiretroviral treatmentâ€“how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Reviews, 2002, 4, 233-41.	1.0	23
113	Reproductive options for HIV-serodiscordant couples. AIDS Reviews, 2006, 8, 158-70.	1.0	23
114	Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIVâ€“hepatitis C virus coinfecting patients. Aids, 2013, 27, 1187-1188.	2.2	22
115	New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy, 2016, 17, 217-229.	1.8	22
116	Elevated TGFâ€“ β 1 levels might protect HCV/â€“HIVâ€“coinfecting patients from liver fibrosis. European Journal of Clinical Investigation, 2011, 41, 70-76.	3.4	21
117	Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. International Journal of Infectious Diseases, 2021, 112, 81-88.	3.3	21
118	Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Reviews, 2022, 24, .	1.0	21
119	Liver Fibrosis Stage and HCV Genotype Distribution in HIVâ€“HCV Coinfecting Patients with Persistently Normal Transaminases. AIDS Research and Human Retroviruses, 2007, 23, 801-804.	1.1	20
120	Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. HIV Clinical Trials, 2007, 8, 98-101.	2.0	20
121	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIVâ€“hepatitis C virus-coinfecting patients with prior nonresponse or relapse. Aids, 2011, 25, 1131-1133.	2.2	20
122	Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. Clinical Infectious Diseases, 2013, 56, 560-566.	5.8	20
123	Hospital admissions in individuals with HTLV-1 infection in Spain. Aids, 2020, 34, 1019-1027.	2.2	20
124	Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Reviews, 2011, 13, 171-9.	1.0	20
125	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. Clinical Infectious Diseases, 2008, 46, 1782-1785.	5.8	19
126	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. Journal of Antimicrobial Chemotherapy, 2008, 62, 626-627.	3.0	18

#	ARTICLE	IF	CITATIONS
127	Comparison of High Ribavirin Induction Versus Standard Ribavirin Dosing, Plus Peginterferon- α for the Treatment of Chronic Hepatitis C in HIV-Infected Patients: The PERICO Trial. <i>Journal of Infectious Diseases</i> , 2012, 206, 961-968.	4.0	18
128	Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Child-Pugh B Compensated Cirrhosis. <i>Antiviral Therapy</i> , 2016, 21, 91-92.	1.0	18
129	HIV type 2 epidemic in Spain. <i>Aids</i> , 2017, 31, 1353-1364.	2.2	18
130	Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1470-1472.	3.0	17
131	Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1421-1434.	2.4	17
132	Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2003, 4, 361-371.	2.0	16
133	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011, 12, 487-493.	2.2	16
134	Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295.	5.8	16
135	Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 475-479.	2.0	16
136	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014, 15, 16-24.	4.1	16
137	Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2015, 20, 329-334.	1.0	16
138	Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72.	1.0	16
139	Hypoglycemia in a diabetic patient during hepatitis C therapy. <i>Hepatology</i> , 2016, 63, 2065-2066.	7.3	16
140	Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain. <i>Antiviral Therapy</i> , 2018, 23, 87-90.	1.0	16
141	Drug interactions in HIV-infected patients treated for hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 807-816.	3.3	16
142	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362.	3.0	16
143	Long-acting antiretroviral therapy. <i>Nature Materials</i> , 2020, 19, 826-827.	27.5	16
144	Why such excess of mortality for COVID-19 in Spain?. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612093275.	1.8	16

#	ARTICLE	IF	CITATIONS
145	Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , 2007, 12, 469-476.	1.0	16
146	Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , 2005, 10, 167-170.	1.0	16
147	Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 392-395.	2.0	15
148	Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , 2013, 27, 2219-2224.	2.2	15
149	Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 5-16.	3.3	15
150	Combinations of nucleoside/nucleotide analogues for HIV therapy. <i>AIDS Reviews</i> , 2004, 6, 234-43.	1.0	15
151	Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1237-1241.	1.1	13
152	Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 440-444.	2.0	13
153	Predicted effect of direct acting antivirals in the current HIV/HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.	1.0	13
154	Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1015-1022.	3.3	13
155	A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008, 22, 911-912.	2.2	12
156	Differences in Virological Response to Peginterferon- α 2a Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123.	2.1	12
157	Different impact of IL28B polymorphisms on response to peginterferon- α 2a plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.	3.1	12
158	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	1.0	12
159	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015, 71, 63-66.	3.1	12
160	Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. <i>Journal of HIV Therapy</i> , 2009, 14, 13-8.	0.6	12
161	Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2005, 41, 897-900.	5.8	11
162	New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. <i>Aids</i> , 2011, 25, 1013-1014.	2.2	11

#	ARTICLE	IF	CITATIONS
163	Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014, 46, 290-296.	3.8	11
164	Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1119-1130.	3.3	11
165	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1427-1435.	2.9	10
166	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	3.3	10
167	Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013, 58, 391-395.	3.1	10
168	Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035.	1.0	10
169	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057.	1.8	10
170	Integral management of COVID-19 in Madrid: Turning things around during the second wave.. <i>Lancet Regional Health - Europe</i> , The, 2021, 2, 100039.	5.6	10
171	Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. <i>Antiviral Therapy</i> , 2004, 9, 987-92.	1.0	10
172	Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. <i>Antiviral Therapy</i> , 2006, 11, 869-77.	1.0	10
173	Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007, 9, 99-113.	1.0	10
174	Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. <i>AIDS Reviews</i> , 2012, 14, 54-61.	1.0	10
175	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008, 5, 86-93.	3.1	9
176	Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803.	1.0	9
177	AIDS Clinical Research in Spain – Large HIV Population, Geniality of Doctors, and Missing Opportunities. <i>Viruses</i> , 2018, 10, 293.	3.3	9
178	Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48.	4.1	9
179	Gene therapy for HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 319-327.	3.1	8
180	Tenofovir for Hepatitis Delta. <i>Hepatology</i> , 2016, 63, 1395-1396.	7.3	8

#	ARTICLE	IF	CITATIONS
181	HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670.	1.6	8
182	Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz036.	0.9	8
183	Envisioning a hepatitis delta cure with new antivirals. <i>Future Microbiology</i> , 2021, 16, 927-930.	2.0	8
184	Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2004, 9, 505-9.	1.0	8
185	Psychopharmacological treatments in HIV patients under antiretroviral therapy. <i>AIDS Reviews</i> , 2012, 14, 101-11.	1.0	8
186	Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948.	5.1	7
187	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.	2.2	7
188	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 179-186.	1.8	7
189	Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986802.	1.8	7
190	SARS-CoV-2 1.1.7 Variant Outbreak in a Fully Vaccinated Nursing Home in Madrid, June 2021. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2266-2268.	2.5	7
191	Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. <i>Aids</i> , 2022, 36, 249-256.	2.2	7
192	First HAART in HIV-Infected Patients With High Viral Load: Value of HIV RNA Levels at 12 Weeks to Predict Virologic Outcome. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009, 8, 314-317.	1.2	6
193	Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424.	1.1	6
194	Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy. <i>Antiviral Therapy</i> , 2013, 19, 287-292.	1.0	6
195	High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2016, 21, 489-494.	1.0	6
196	Need to Face Liver Cirrhosis after HCV Cure with Antivirals. <i>EBioMedicine</i> , 2017, 24, 24-25.	6.1	6
197	Diagnosis of cutaneous anthrax in resource-poor settings in West Arsi Province, Ethiopia. <i>Annals of Agricultural and Environmental Medicine</i> , 2017, 24, 712-715.	1.0	6
198	Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. <i>Travel Medicine and Infectious Disease</i> , 2020, 33, 101543.	3.0	6

#	ARTICLE	IF	CITATIONS
199	Unveiling Long COVID-19 Disease. <i>AIDS Reviews</i> , 2021, 22, 227-228.	1.0	6
200	Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 657-62.	1.0	6
201	Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19. <i>Vaccines</i> , 2022, 10, 383.	4.4	6
202	Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2022, 29, 777-784.	2.0	6
203	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	2.0	6
204	Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors. <i>HIV Clinical Trials</i> , 2005, 6, 50-61.	2.0	5
205	Very Late HCV Relapse following Triple Therapy for Hepatitis C. <i>Antiviral Therapy</i> , 2014, 19, 723-724.	1.0	5
206	Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. <i>Liver International</i> , 2016, 36, 763-763.	3.9	5
207	Malaria and severe anemia over eight years at Gambo Rural Hospital, southern Ethiopia. <i>Pathogens and Global Health</i> , 2017, 111, 195-199.	2.3	5
208	Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon α 2a or α 2b. <i>Antiviral Therapy</i> , 2008, 13, 511-517.	1.0	5
209	Induction-Maintenance (5 α 3 Drugs) in HIV-Infected Patients with High Viral Load. <i>AIDS Patient Care and STDs</i> , 2000, 14, 573-574.	2.5	4
210	Prevalence of positive HIV, HBV, HCV and treponemal tests in blood donors in a rural hospital in southern Ethiopia. <i>Journal of Clinical Virology</i> , 2016, 77, 60-62.	3.1	4
211	COVID-19 Comes 40 Years After AIDS - Any Lesson?. <i>AIDS Reviews</i> , 2021, 22, 63-77.	1.0	4
212	Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case. <i>Viruses</i> , 2021, 13, 917.	3.3	4
213	Infection and infectivity: Utility of rapid antigen tests for the diagnosis of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 46-48.	1.3	4
214	Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. <i>Hepatology International</i> , 2022, 16, 1161-1169.	4.2	4
215	Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011, 18, 542-548.	2.0	3
216	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013, 12, 269-275.	0.3	3

#	ARTICLE	IF	CITATIONS
217	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	3.3	3
218	A case of acute generalized exanthematous pustulosis caused by exposure to Atovaquone/proguanil. <i>Journal of Travel Medicine</i> , 2020, 27, .	3.0	3
219	Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020, 22, 168-172.	1.0	3
220	Nucleoside/nucleotide backbones for the treatment of HIV infection. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 812-22.	2.3	3
221	Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 866-871.	2.0	2
222	Is Ribavirin Teratogenic in Humans? No Evidence So Far. <i>Drug Safety</i> , 2017, 40, 1163-1165.	3.2	2
223	Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections. <i>AIDS Reviews</i> , 2020, 22, 124-127.	1.0	2
224	Integral management of COVID-19 in Madrid: Turning things around during the second wave” Authors' reply. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100076.	5.6	2
225	Use of antibiotics in respiratory viral infections. <i>Internal and Emergency Medicine</i> , 2022, 17, 1569-1570.	2.0	2
226	Is there a role for indinavir twice-daily in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2000, 6, 152-154.	6.0	1
227	Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice. <i>Journal of the International AIDS Society</i> , 2010, 13, P35.	3.0	1
228	Long-term treatment of patients with HIV-1: the role of atazanavir. <i>HIV/AIDS - Research and Palliative Care</i> , 2010, 2, 157.	0.8	1
229	HCV and HIV Coinfection. <i>Current Hepatitis Reports</i> , 2011, 10, 52-61.	0.3	1
230	Virological Correlates of IgM–IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted Antigens. <i>Viruses</i> , 2021, 13, 874.	3.3	1
231	More pre-exposure prophylaxis for rising HIV infection?. <i>AIDS Reviews</i> , 2014, 16, 118-9.	1.0	1
232	News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis. <i>AIDS Reviews</i> , 2023, 24, .	1.0	1
233	Monthly Cyclic Therapy in Heavily Pretreated HIV-Infected Patients. <i>AIDS Patient Care and STDs</i> , 2001, 15, 177-179.	2.5	0
234	Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy. <i>Journal of the International AIDS Society</i> , 2010, 13, P208-P208.	3.0	0

#	ARTICLE	IF	CITATIONS
235	Delta hepatitis: new approaches to therapy. <i>Future Virology</i> , 2016, 11, 197-205.	1.8	0
236	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa320.	0.9	0
237	The importance of (at least) a clinical typification of non-typeable <i>Haemophilus influenzae</i> infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 57-58.	0.5	0
238	Approach to COVID-19 pandemic management in Madrid. <i>Chronic of a year. Revista Espanola De Quimioterapia</i> , 2021, 34, 76-80.	1.3	0
239	The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 242-244.	2.0	0
240	Social Restrictions Versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0